Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ifetroban sodium |
Synonyms | |
Therapy Description |
Ifetroban sodium (BMS-180291) is an antagonist of the Thromboxane A2 and Prostaglandin H2 receptors, which inhibits activation and downstream signaling potentially resulting in decreased tumor metatstasis (PMID: 26036247). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ifetroban sodium | BMS-180291 | Ifetroban sodium (BMS-180291) is an antagonist of the Thromboxane A2 and Prostaglandin H2 receptors, which inhibits activation and downstream signaling potentially resulting in decreased tumor metatstasis (PMID: 26036247). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03694249 | Phase II | Ifetroban sodium | Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | Active, not recruiting | USA | 0 |